Literature DB >> 25629569

Comparing outcomes of stereotactic body radiotherapy with intensity-modulated radiotherapy for patients with locally advanced unresectable pancreatic cancer.

Jang-Chun Lin1, Yee-Min Jen, Ming-Hsien Li, Hsing-Lung Chao, Jo-Ting Tsai.   

Abstract

OBJECTIVES: Survival in patients with locally advanced unresectable pancreatic cancer (LAUPC) is poor, and local recurrence continues to be a major problem in the management of this disease. Radiotherapy (RT) using different RT techniques, including intensity-modulated radiotherapy (IMRT) and stereotactic body radiation therapy (SBRT), may lead to different clinical outcomes for patients with LAUPC. Here, we compared SBRT with IMRT for patients with LAUPC with respect to survival rate, local control (LC) rate, and toxicity-related dose distribution.
MATERIALS AND METHODS: This retrospective study from March 2007 to March 2011 included 41 patients with LAUPC who were divided into two groups, with 20 patients receiving SBRT and 21 patients receiving IMRT. The median follow-up time was 16 months.
RESULTS: For the IMRT and SBRT groups, the median survival times were 13 and 20 months, and 1-year overall survival (OS) rates were 70.7 and 80.0%, respectively. There was no difference in OS between the two RT techniques. RT with SBRT showed significantly better local disease-free survival than IMRT for patients with LAUPC. Tobacco use had a borderline effect on LC. Thus, further statistical analysis showed that patients who used tobacco had better LC after receiving SBRT than IMRT.
CONCLUSION: SBRT improved LC for LAUPC patients and had similar radiation toxicity compared with IMRT. Further study is required to define the effects of administered radiation dose and fractionation, as well as to further expand the sample size, to use a prospective study, and to observe the long-term efficacy of these techniques.

Entities:  

Mesh:

Year:  2015        PMID: 25629569     DOI: 10.1097/MEG.0000000000000283

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  13 in total

Review 1.  Stereotactic body radiotherapy for the pancreas: a critical review for the medical oncologist.

Authors:  Samuel K Kim; Cheng-Chia Wu; David P Horowitz
Journal:  J Gastrointest Oncol       Date:  2016-06

2.  Comparative efficacy and safety of neoadjuvant radiotherapy for patients with borderline resectable, and locally advanced pancreatic ductal adenocarcinoma: a systematic review and network meta-analysis protocol.

Authors:  Wanrui Lv; Qingfeng Wang; Qiancheng Hu; Xin Wang; Dan Cao
Journal:  BMJ Open       Date:  2022-07-13       Impact factor: 3.006

3.  Assessing the Magnitude of Immunogenic Cell Death Following Chemotherapy and Irradiation Reveals a New Strategy to Treat Pancreatic Cancer.

Authors:  Jian Ye; Bradley N Mills; Tony Zhao; Booyeon J Han; Joseph D Murphy; Ankit P Patel; Carl J Johnston; Edith M Lord; Brian A Belt; David C Linehan; Scott A Gerber
Journal:  Cancer Immunol Res       Date:  2019-11-12       Impact factor: 11.151

4.  Dosimetric feasibility on hypofractionated intensity-modulated radiotherapy and simultaneous integrated boost for locally advanced unresectable pancreatic cancer with helical tomotherapy.

Authors:  Feng Teng; Lingling Meng; Fuhai Zhu; Gang Ren
Journal:  J Gastrointest Oncol       Date:  2021-04

5.  Prognostic role of stereotactic body radiation therapy for elderly patients with advanced and medically inoperable pancreatic cancer.

Authors:  Xiaofei Zhu; Fuqi Li; Xiaoping Ju; Fei Cao; Yangsen Cao; Fang Fang; Shuiwang Qing; Yuxin Shen; Zhen Jia; Huojun Zhang
Journal:  Cancer Med       Date:  2017-08-23       Impact factor: 4.452

Review 6.  Stereotactic Body Radiation Therapy in the Management of Upper GI Malignancies.

Authors:  Leila Tchelebi; Nicholas Zaorsky; Heath Mackley
Journal:  Biomedicines       Date:  2018-01-03

7.  Dosimetric and radiobiological comparison of treatment plan between CyberKnife and EDGE in stereotactic body radiotherapy for pancreatic cancer.

Authors:  Zhi-Tao Dai; Li Ma; Ting-Ting Cao; Lian Zhu; Man Zhao; Ning Li
Journal:  Sci Rep       Date:  2021-02-18       Impact factor: 4.379

8.  MR-guided adaptive stereotactic body radiotherapy (SBRT) of primary tumor for pain control in metastatic pancreatic ductal adenocarcinoma (mPDAC): an open randomized, multicentric, parallel group clinical trial (MASPAC).

Authors:  M Pavic; M Niyazi; L Wilke; S Corradini; M Vornhülz; U Mansmann; A Al Tawil; R Fritsch; J Hörner-Rieber; J Debus; M Guckenberger; C Belka; J Mayerle; G Beyer
Journal:  Radiat Oncol       Date:  2022-01-25       Impact factor: 3.481

9.  New Potential Options for SBRT in Pancreatic Cancer.

Authors:  Maged Ghaly; Emile Gogineni; Joseph Herman; Muhammad W Saif
Journal:  Cancer Med J       Date:  2021-02-18

10.  Stereotactic body radiotherapy vs conventionally fractionated chemoradiation in locally advanced pancreatic cancer: A multicenter case-control study (PAULA-1).

Authors:  Alessandra Arcelli; Milly Buwenge; Gabriella Macchia; Federica Bertini; Alessandra Guido; Francesco Deodato; Savino Cilla; Valerio Scotti; Maria Elena Rosetto; Igor Djan; Salvatore Parisi; Gian Carlo Mattiucci; Francesco Cellini; Michele Fiore; Pierluigi Bonomo; Liliana Belgioia; Rita Marina Niespolo; Pietro Gabriele; Mariacristina Di Marco; Nicola Simoni; Renzo Mazzarotto; Alessio Giuseppe Morganti
Journal:  Cancer Med       Date:  2020-09-10       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.